Q-omics provides the consensus-scored MIR196A1 profile across patient tissues and cancer cell-line models. MIR196A1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, MIR196A1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MIR196A1 RNA expression shows 14,302 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight THYM, HNSC, and KIRP as cancer lineages where MIR196A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR196A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR196A1 survival associations across molecular data types. MIR196A1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR196A1 RNA expression–survival associations across cancer types. High MIR196A1 expression shows unfavorable associations in THYM, KIRC, UCEC and HNSC, but favorable associations in READ and UCS. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for MIR196A1 RNA expression.
This table summarizes MIR196A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR196A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR196A1 shows lower tumor expression in KIRC and higher tumor expression in HNSC, STAD, UCEC, LUSC and BRCA. The HNSC box plot shows higher MIR196A1 RNA expression in tumor versus normal tissue (log2 FC = +1.488, t-test p < 0.001).
This table shows molecular features associated with MIR196A1 in patient tissues and cancer cell lines. In patient samples, MIR196A1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
